NEW YORK, Feb 18 (Reuters) - Johnson & Johnson said it has recalled two lots of Simponi injection devices -- one in the United States and one in Europe -- after discovering they may deliver less than ...

If you have a certain kind of autoimmune condition, your doctor might suggest Simponi or Simponi Aria as a treatment option for you. The active ingredient in Simponi and Simponi Aria is golimumab. An ...

Two interchangeable golimumab biosimilars were approved for the treatment of rheumatoid arthritis and ulcerative colitis.

The Simponi recall stemmed from a manufacturing problem in Switzerland. As Dow Jones reports, many of the affected lots were set aside before hitting the market, but some 395 of the prefilled ...

Johnson & Johnson has recalled lots of its Simponi injections for possible substandard dosage of its arthritis treatment, according to a Reuters news report. A Johnson & Johnson spokesperson said ...

April 27, 2009 — The US Food and Drug Administration (FDA) has approved golimumab (Simponi, Centocor Ortho Biotech Inc) for monthly subcutaneous injection in the treatment of adults with ...

The U.S. Food and Drug Administration today approved a new use for Simponi (golimumab) injection to treat adults with moderate to severe ulcerative colitis. Simponi works by blocking tumor necrosis ...

Golimumab 50mg/4mL; soln for IV infusion after dilution; preservative- and latex-free. Simponi Aria (golimumab) Injection is a colorless to light yellow solution available in packs of 1 vial. Each ...

The FDA has approved two TNF inhibitor golimumab-sldi biosimilars, Immgolis and Immgolis Intri, as interchangeable with the golimumab reference products Simponi and Simponi Aria, according to an ...

For the third time this week, we're reporting on a Johnson & Johnson recall. (See hereand herefor the other two.) This time the recall seems to involve only a few hundred units. As Dow Jones Newswires ...

NEW YORK, Oct 17 (Reuters) - Johnson & Johnson's new rheumatoid arthritis drug, Simponi, when used in combination with the common treatment methotrexate was significantly more effective at inhibiting ...

HONG KONG – Xian Janssen Pharmaceutical Ltd. has launched Simponi (golimumab injection), making it the first once-monthly self-injectable anti-TNF biologic for patients with active ankylosing ...